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Does Preventing Rotavirus Infections Through Vaccination Also 
Protect Against Naturally Occurring Intussusception Over Time?
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To the Editor
Intestinal intussusception is an uncommon event (incidence approximately 30 per 100 000 
per year in US infants) in which one part of the intestine folds into another. The condition is 
usually considered idiopathic, but numerous case reports link intussusception to enteric 
pathogens, notably adenovirus. Several case reports have linked wild-type rotavirus to 
intussusception, although evidence for this link is inconclusive [1].
In 1999, a previous rotavirus vaccine (Rotashield) was found to be associated with 
intussusception [2] and was withdrawn from the US market. Currently, 2 rotavirus vaccines 
are routinely administered to US infants: RotaTeq and Rotarix. Large clinical trials (>60 000 
children each) found no statistical association between vaccination and intussusception 
within 42 days following any dose [3, 4]. Nonetheless, with the accumulation of study 
power over time, recent postlicensure rotavirus vaccine safety assessments in the United 
States [5,6] report a modest but significant risk of intussusception.
One could postulate that if vaccines based on 3 different live-attenuated rota-virus vaccine 
strains (rhesus in Rota-shield, bovine-human reassortants in RotaTeq, and human rotavirus 
in Rotar-ix) are statistically associated with intussusception, then the wild-type rotavirus 
(naturally nonattenuated and most virulent) could also plausibly be associated with 
intussusception. We studied a vaccine probe hypothesis: If wild-type rotavirus infection is 
causally associated with intussusception, then the prevention of such infections through 
vaccination could conceivably protect against intussusception during time periods after 
vaccination.
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To assess whether children protected by rotavirus vaccine were at lower risk for 
intussusception in the first year after completing their full vaccine series, we retrospectively 
analyzed a cohort of children born after rotavirus vaccine licen-sure (February 2006) and 
enrolled in the Vaccine Safety Datalink (VSD), a collaboration of managed care 
organizations capturing medical visits and vaccination data on more than 9 million 
individuals. Intussusception cases had ICD9-CM code 560.0 (intussusception) and 543.9 
(other and unspecified diseases of appendix) in VSD hospitalization or emergency room 
automated data files. Based on previously published results, VSD's positive predictive value 
for these ICD-9-CM codes was 75% [7]. We calculated rates of intussusception from 4 to 55 
weeks following last rotavirus vaccination among children receiving a full course of 
rotavirus vaccinations, limiting our analysis to those children having at least 1 other 
recommended vaccine. A time-to-event analysis using a Cox proportional hazards model 
accounted for gender, age at last vaccine dose, seasonality, VSD site, and index year of 
intussusception event.
Our cohort contained VSD data on 186 488 children receiving a full course of rotavirus 
vaccines and 64 089 children receiving none. We found 50 cases of intussusception among 
the vaccinated children (0.027%) and 22 cases amongb the children receiving no rotavirus 
vaccine (0.034%). Compared with children receiving no rotavirus vaccine, the incidence of 
intussusception among the vaccinated children was not statistically different (incidence rate 
ratio = 0.94 [95% confidence interval (CI), .50, 1.75]).
Previous analyses conducted before and after introduction of Rotashield [8] suggested that 
rotavirus vaccine receipt perhaps triggered “early-onset” intussusceptions among children 
biologically predisposed to experience this condition, which would then be followed by a 
period of compensatory, decreased risk later in infancy. A similar finding was suggested 
during a prelicensure randomized clinical trial of Rotarix, whereupon the relative risk of 
intussusception decreased from 0.56 (95% CI, .25, 1.24) for the 0–100 day postvaccination 
interval to 0.28 (95% CI, .10, .81) during the 0–1 year postvaccination interval [9].
Our findings, derived from a well-powered sample having good clinical and vaccine 
exposure accuracy, indicate that the risk of naturally occurring intussusception was not 
modified by rotavirus vaccination during the period of 1 month to 1 year following 
vaccination.
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